Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

NCT01268358 | Completed Phase 1 DMC

• 2 other identifiers: rhLAMAN-022010-022084-36
• Study Type: interventional
• Target: 10
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a single-center, open-label, dose escalation study of patients with alpha-mannosidosis. 10 patients will be enrolled in this study receiving intravenous infusions of Lamazym. In order to avoid development of delayed hypersensitivity all patients will continue weekly treatment at the designated dose until the Safety Committee approves transfer to the rhLAMAN-03 protocol. It is the hypothesis that Lamazym is safe to use.

Conditions

Alpha Mannosidosis

Outcome Measures

Primary Outcomes (1)

• To evaluate the safety profile of rhLAMAN (Lamazym)

  1-5 weeks

Secondary Outcomes (2)

• To determine the PK profile of rhLAMAN (Lamazym) in patients with alpha-mannosidosis as measured by rhLAMAN levels in plasma

  1 dosis

• To collect baseline measurements that are to be used for efficacy evaluation in the following trial (rhLAMAN-03)

  1 week

Study Arms (5)

Lamazym 6.25

EXPERIMENTAL

Drug: Lamazym

Lamazym 12.5

EXPERIMENTAL

Drug: Lamazym

Lamazym 25

EXPERIMENTAL

Drug: Lamazym

Lamazym 50

EXPERIMENTAL

Drug: Lamazym

Lamazym 100

EXPERIMENTAL

Drug: Lamazym

Interventions

Lamazym DRUG

Lamazym, ERT, infusion weekly

Also known as: rhLAMAN

Lamazym 100; Lamazym 12.5; Lamazym 25; Lamazym 50; Lamazym 6.25

Eligibility Criteria

• Age: 5 Years - 20 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• The patient must have a confirmed diagnosis of alpha-mannosidosis as defined by alpha-mannosidase activity \< 10% of normal activity in blood leukocytes
• The patient must have an age at the time of screening ≥ 5 year and ≤ 20 years
• The patient must have physical ability to perform 6-minutes walk test (6MWT), 3 minute-stair climb test (3MSCT) and pulmonary lung function test (spirometry, body plethysmography).
• The patient must have the ability to mentally cooperate in the cognitive and motor function tests
• The patient must have the ability to hear and follow a request. Hearing aids can be worn.
• Patient or patient's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject)
• The patient and his/her guardian(s) must have the ability to comply with the protocol

You may not qualify if:

• The patient cannot walk without support.
• Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-mannosidosis
• History of bone marrow transplantation
• Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial
• Presence of an ECHO with abnormalities within half a year that, in the opinion of the Investigator, would preclude participation in the trial
• Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial
• Pregnancy
• Psychosis within the last 3 months

Sponsors & Collaborators

• Zymenex A/S: lead
• European Commission: collaborator

Related Publications (3)

• Borgwardt L, Thuesen AM, Olsen KJ, Fogh J, Dali CI, Lund AM. Cognitive profile and activities of daily living: 35 patients with alpha-mannosidosis. J Inherit Metab Dis. 2015 Nov;38(6):1119-27. doi: 10.1007/s10545-015-9862-4. Epub 2015 May 28.

  PMID: 26016802 BACKGROUND

• Borgwardt L, Dali CI, Fogh J, Mansson JE, Olsen KJ, Beck HC, Nielsen KG, Nielsen LH, Olsen SO, Riise Stensland HM, Nilssen O, Wibrand F, Thuesen AM, Pearl T, Haugsted U, Saftig P, Blanz J, Jones SA, Tylki-Szymanska A, Guffon-Fouiloux N, Beck M, Lund AM. Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study. J Inherit Metab Dis. 2013 Nov;36(6):1015-24. doi: 10.1007/s10545-013-9595-1. Epub 2013 Mar 14.

  PMID: 23494656 RESULT

• Borgwardt L, Stensland HM, Olsen KJ, Wibrand F, Klenow HB, Beck M, Amraoui Y, Arash L, Fogh J, Nilssen O, Dali CI, Lund AM. Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation. Orphanet J Rare Dis. 2015 Jun 6;10:70. doi: 10.1186/s13023-015-0286-x.

  PMID: 26048034 RESULT

Related Links

• Study Record on EU Clinical Trials Register including results

MeSH Terms

Conditions

alpha-Mannosidosis

Condition Hierarchy (Ancestors)

Mannosidase Deficiency Diseases; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Lysosomal Storage Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Allan M. Lund, MD

  Department of Clinical Genetics, Juliane Marie Centre, Region Hovedstaden, Copenhagen University hospital, Denmark

  PRINCIPAL INVESTIGATOR

• Jens Fogh

  Zymenex A/S

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 29, 2010
• First Posted: December 30, 2010
• Study Start: October 1, 2010
• Primary Completion: January 1, 2011
• Study Completion: January 1, 2011
• Last Updated: August 3, 2020

Record last verified: 2020-07